A new therapy called Vixarelimab has shown rapid, sustained clinical benefits in prurigo nodularis. Although most details remain behind paid content, this announcement highlights potentially encouraging news for those affected by this skin condition.

New research suggests that dermatological issues, such as rashes or itching, could be a sign of heightened risk of depression and suicidal thoughts among people experiencing their first psychotic episode. Findings show that 25% of patients with these skin problems report suicidal ideation, significantly higher than the 7% of those without such symptoms.